Free Trial

Physiomics (PYC) Competitors

Physiomics logo
GBX 0.40 -0.03 (-5.81%)
As of 11:28 AM Eastern

PYC vs. EVG, MTFB, DEST, ROQ, VAL, RENE, BSFA, SALV, OVB, and ONC

Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), ValiRx (VAL), ReNeuron Group (RENE), BSF Enterprise (BSFA), SalvaRx Group (SALV), Ovoca Bio (OVB), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry.

Physiomics vs.

Evgen Pharma (LON:EVG) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.

27.8% of Evgen Pharma shares are owned by institutional investors. 32.4% of Evgen Pharma shares are owned by insiders. Comparatively, 4.2% of Physiomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Evgen Pharma has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Physiomics has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500.

Evgen Pharma received 113 more outperform votes than Physiomics when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
Evgen PharmaOutperform Votes
193
74.23%
Underperform Votes
67
25.77%
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%

In the previous week, Evgen Pharma had 1 more articles in the media than Physiomics. MarketBeat recorded 1 mentions for Evgen Pharma and 0 mentions for Physiomics. Physiomics' average media sentiment score of 0.00 beat Evgen Pharma's score of -0.84 indicating that Physiomics is being referred to more favorably in the news media.

Company Overall Sentiment
Evgen Pharma Negative
Physiomics Neutral

Evgen Pharma has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Evgen Pharma's return on equity of -60.57% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Evgen PharmaN/A -60.57% -45.52%
Physiomics -106.80%-127.68%-76.38%

Physiomics has higher revenue and earnings than Evgen Pharma. Physiomics is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evgen PharmaN/AN/A-£3.35M-£0.01N/A
Physiomics£864.07K0.96-£922.82K-£0.45-0.91

Summary

Evgen Pharma beats Physiomics on 9 of the 14 factors compared between the two stocks.

Remove Ads
Get Physiomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYC vs. The Competition

MetricPhysiomicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£831,000.00£107.79M£5.59B£2.57B
Dividend Yield6.20%3.78%5.37%4.95%
P/E Ratio-0.913.1023.59140.01
Price / Sales0.964,194.85371.05262,597.18
Price / Cash4.2112.7538.1727.90
Price / Book1.9435.776.674.53
Net Income-£922,817.80-£91.48M£3.20B£5.76B
7 Day Performance-6.03%-4.22%-5.58%0.34%
1 Month Performance-15.63%58.78%-0.75%5.74%
1 Year Performance-68.85%82.71%7.88%107.79%

Physiomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
N/AGBX 0.41
-5.8%
N/A-67.7%£831,000.00£864,071.75-0.9110Gap Down
EVG
Evgen Pharma
N/AN/AN/AN/A£3.42MN/A-80.0010
MTFB
Motif Bio
N/AN/AN/AN/A£3.28MN/A-0.036
DEST
Destiny Pharma
N/AN/AN/AN/A£2.87M£135,028.00-50.0024Gap Down
High Trading Volume
ROQ
Roquefort Therapeutics
N/AGBX 1.87
-1.8%
N/A-77.1%£2.37M£2,662.35-1.549High Trading Volume
VAL
ValiRx
N/AGBX 0.60
+4.3%
N/A-84.8%£2.28M£27,777.32-0.405,450Gap Up
RENE
ReNeuron Group
N/AN/AN/AN/A£1.93M£783,000.00-37.502Gap Down
BSFA
BSF Enterprise
N/AGBX 1.50
+9.1%
N/A-72.9%£1.85M£80,250.74-0.9112Gap Up
SALV
SalvaRx Group
N/AN/AN/AN/A£1.65M£64.50M0.032Gap Up
OVB
Ovoca Bio
N/AGBX 1.40
flat
N/A+92.9%£1.41MN/A-1.295
ONC
Oncimmune
N/AGBX 1.14
flat
N/AN/A£1.29M£1.86M0.1352Negative News
Remove Ads

Related Companies and Tools


This page (LON:PYC) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners